Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 327

1.

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M.

BMJ. 1999 Mar 6;318(7184):633-8. Erratum in: BMJ 2001 Jun 16;322(7300):1456.

2.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(4):CD001191. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD001191.

PMID:
11034705
3.

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B.

Neurology. 1998 May;50(5):1222-30.

PMID:
9595967
4.
5.

Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.

Farlow M, Potkin S, Koumaras B, Veach J, Mirski D.

Arch Neurol. 2003 Jun;60(6):843-8.

PMID:
12810489
6.

Rivastigmine for Alzheimer's disease.

Birks J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(2):CD001191. Review. Update in: Cochrane Database Syst Rev. 2000;(4):CD001191.

PMID:
10796621
7.

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.

Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D.

J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):589-95.

8.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
9.

Rivastigmine for Alzheimer's disease.

Birks JS, Grimley Evans J.

Cochrane Database Syst Rev. 2015 Apr 10;(4):CD001191. doi: 10.1002/14651858.CD001191.pub3. Review.

PMID:
25858345
10.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;4:CD001191.

PMID:
19370562
11.

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.

Farlow MR, Grossberg GT, Meng X, Olin J, Somogyi M.

Int J Geriatr Psychiatry. 2011 Dec;26(12):1236-43. doi: 10.1002/gps.2669. Epub 2010 Dec 23.

PMID:
22068922
12.
13.

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.

Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R.

Arch Neurol. 2001 Mar;58(3):417-22.

PMID:
11255445
15.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
16.

A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.

Karaman Y, Erdoğan F, Köseoğlu E, Turan T, Ersoy AO.

Dement Geriatr Cogn Disord. 2005;19(1):51-6. Epub 2004 Sep 21.

17.

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT.

Dement Geriatr Cogn Disord. 1999 May-Jun;10(3):237-44.

PMID:
10325453
19.

Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.

Chiu PY, Dai DE, Hsu HP, Lee C, Lin JJ, Kuo HC, Huang YC, Liu YC, Tsai CP.

Clin Drug Investig. 2009;29(11):729-38. doi: 10.2165/11315320-000000000-00000.

PMID:
19813776
20.

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.

Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacoby R.

BMJ. 2005 Apr 16;330(7496):874. Epub 2005 Feb 18.

Supplemental Content

Support Center